Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Secondary AML in first remission predicts outcomes

Key clinical point: Secondary acute myeloid leukemia in first complete remission appears to predict outcomes after stem cell transplant.

Major finding: Secondary acute myeloid leukemia in first complete remission was associated with higher nonrelapse mortality (hazard ratio, 1.32) and cumulative incidence of relapse (HR, 1.28), and with lower leukemia-free survival (HR, 1.30), overall survival (HR, 1.32), and graft-versus-host disease/relapse free survival (HR, 1.20).

Study details: A large registry-based analysis involving more than 12,700 patients with de novo or secondary acute myeloid leukemia.

Disclosures: Dr. Savani reported having no financial disclosures.

Citation:

Savani B et al. TCT 2019, Abstract 12.